Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6155
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Stakeholders
- Companies sponsors
- AstraZeneca
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Accord-UK Ltd (bendamustine) – confidentiality agreement not signed, not participating
- Aspire Pharma (bortezomib) – confidentiality agreement not signed, not participating
- Aurobindo Pharma (bortezomib) – confidentiality agreement not signed, not participating
- Baxter Healthcare Ltd (cyclophosphamide, doxorubicin) – confidentiality agreement not signed, not participating
- Biotech Pharma (bortezomib) – confidentiality agreement not signed, not participating
- Celltrion Healthcare UK Ltd (rituximab) – confidentiality agreement not signed, not participating
- Dr Reddy’s Laboratories UK Ltd (bendamustine, bortezomib) – confidentiality agreement not signed, not participating
- Hospira UK Ltd (cytarabine, vincristine) – confidentiality agreement not signed, not participating
- Jazz Pharmaceuticals UK (cytarabine) – confidentiality agreement not signed, not participating
- Johnson & Johnson Ltd (bortezomib) – confidentiality agreement not signed, not participating
- medac GmbH (bortezomib, doxorubicin) – confidentiality agreement not signed, not participating
- MSN Laboratories Europe (bortezomib) – confidentiality agreement not signed, not participating
- Mylan (bortezomib) – confidentiality agreement not signed, not participating
- Pfizer Ltd (bortezomib, doxorubicin, rituximab) – confidentiality agreement not signed, not participating
- Roche Products Ltd (rituximab) – confidentiality agreement not signed, not participating
- Sandoz Ltd (bortezomib, cyclophosphamide, rituximab) – confidentiality agreement not signed, not participating
- Seacross Pharmaceuticals Ltd (bendamustine, doxorubicin) – confidentiality agreement not signed, not participating
- Sun Pharma (bortezomib) – confidentiality agreement not signed, not participating
- Thornton & Ross Ltd (bortezomib) – confidentiality agreement not signed, not participating
- Tillomed Laboratories Ltd (bortezomib) – confidentiality agreement not signed, not participating
- Zentiva Pharma Ltd (bendamustine) – confidentiality agreement not signed, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 September 2024 | Invitation to participate |
| 23 July 2024 - 20 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6155 |
| 23 July 2024 | In progress. Scoping commenced. |
| 25 April 2023 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma [ID6155]. Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. |
| 11 July 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual